Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine in Mantle Cell Lymphoma
NCT00234026Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in mantle cell lymphoma (MCL), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Objective Response Rate. Started Jun 2005; status: completed.
02
Drugs
gemcitabine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00234026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234026.